Article

DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysis

2023-03-10

Abstract excerpt

<h4>Purpose: </h4> Single-agent immune checkpoint inhibitor (IO) therapy is the standard of care for non-oncogene addicted advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥ 50%. High tumor mutation burden (H-TMB) is a notable biomarker for IO response. Smoking-induced harm generates H-TMB in smoking aNSCLC patients (S-pts), whereas never-smoking patients (NS-pts) usually have low TMB and are IO-unresponsiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4a091812-c6e0-5fb3-88be-7291a0232071
DOI: 10.21203/rs.3.rs-2651331/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysisDOI 10.21203/rs.3.rs-2651331/v1Read

Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.Semantic proximity Read

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung CancerSemantic proximity Read

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung CancerSemantic proximity Read

Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer.Semantic proximity Read

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.Semantic proximity Read

Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma.Semantic proximity Read

Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.Semantic proximity Read

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinomaSemantic proximity Read

RNA sequencing identifies lung cancer lineage and facilitates drug repositioningSemantic proximity Read

Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients.Semantic proximity Read

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor typesSemantic proximity Read